+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line of Therapy, Biomarker Expression, Distribution Channel - Global Forecast to 2030- Product Image
Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line of Therapy, Biomarker Expression, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line of Therapy, Biomarker Expression, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968594
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Non-small Cell Lung Cancer Therapeutics Market grew from USD 17.94 billion in 2024 to USD 19.40 billion in 2025. It is expected to continue growing at a CAGR of 7.79%, reaching USD 28.15 billion by 2030.

Unveiling Critical Dimensions in Non-Small Cell Lung Cancer Care

Non-small cell lung cancer (NSCLC) remains one of the most challenging oncology segments, accounting for a significant proportion of lung cancer diagnoses worldwide. Recent advances in molecular targeting and immunomodulation have revolutionized the therapeutic landscape, offering renewed hope to patients and clinicians alike. However, the complexity of treatment algorithms, the heterogeneity of tumor biology, and the evolving regulatory and economic environment demand a cohesive and forward-looking perspective.

This executive summary synthesizes the pivotal shifts shaping NSCLC therapeutics, from breakthrough immunotherapies to the nuanced impact of trade policies. It delivers a clear-eyed overview of market forces, segmentation insights, and regional dynamics, all against the backdrop of rapid scientific progress. Leaders in biopharma, healthcare delivery, and policy will find this analysis indispensable for aligning investments and strategies with the trajectory of innovation. By weaving together clinical developments, competitive intelligence, and actionable recommendations, this summary paints a compelling picture of where the NSCLC market is today and where it is headed.

Paradigm-Shifting Innovations Driving Next-Generation Treatments

The NSCLC landscape has undergone transformative shifts that extend far beyond incremental advances. Immunotherapy has redefined the standard of care, moving from salvage strategies in later lines to cornerstone first-line regimens. Checkpoint inhibitors targeting PD-1 and PD-L1 pathways now compete directly with traditional platinum-based chemotherapy, driven by compelling survival data and increasingly refined patient selection through biomarker profiling. Concurrently, targeted therapies against EGFR, ALK, ROS1, and emerging KRAS mutations have moved from niche indications into mainstream adoption, enabled by companion diagnostics and the advent of next-generation inhibitors that overcome resistance mutations.

Parallel to clinical innovation, partnership models between pharmaceutical companies, academic centers, and digital health providers have accelerated drug development and real-world evidence generation. Adaptive trial designs and decentralized research platforms are reducing time-to-market and broadening patient access. Moreover, evolving reimbursement frameworks tied to value-based outcomes are reshaping pricing strategies, prompting companies to demonstrate long-term survival benefits and quality-of-life improvements. These synergistic shifts in science, collaboration, and economics have collectively redefined the NSCLC market, setting the stage for sustained expansion and competitive differentiation.

Assessing Tariff-Induced Dynamics in U.S. Oncology Supply Chains

In 2025, the imposition of tariffs on critical reagents, diagnostic kits, and biologic agents in the United States has introduced new layers of complexity and cost considerations for stakeholders. The immediate effect has been an uptick in the landed cost of immuno-oncology agents and precision diagnostics imported from key markets in Europe and Asia-Pacific. Manufacturers have begun reallocating manufacturing footprints closer to the U.S. to mitigate duties, but supply chain reconfiguration introduces its own set of logistical and quality assurance challenges.

From a clinical operations standpoint, hospitals and clinics face increased procurement costs for monoclonal antibodies and novel biomarker assays, which may translate into tighter budget allocations for other oncology services. Payers are responding by revising reimbursement ceilings and demanding more rigorous pharmacoeconomic evidence to justify higher unit prices. On the research side, collaborative trials that span multiple geographies are experiencing budgetary pressure, with sponsors negotiating cost-sharing arrangements to offset tariff-driven expenses. Although the full downstream impact on patient access and long-term R&D investments remains under observation, this policy shift underscores the critical interplay between international trade policies and oncology innovation.

Deep-Dive into Multifaceted Market Segmentations

Segmentation by treatment type reveals that immunotherapies dominate recent pipelines and revenue streams, with CTLA-4 inhibitors like ipilimumab establishing foundational combination regimens, while PD-1 inhibitors such as nivolumab and pembrolizumab continue to expand their indications into earlier lines of therapy. PD-L1 inhibitors including atezolizumab, avelumab and durvalumab are similarly gaining traction, driven by both monotherapy and chemoimmunotherapy approvals. Targeted therapies are evolving in parallel, with ALK and ROS1 inhibitors carving out distinct patient cohorts, and EGFR inhibitors advancing through first, second and third-generation molecules to address resistance mechanisms. Chemotherapy retains a role, particularly in resource-constrained settings, but its relative share is contracting as precision approaches proliferate.

When examining lines of therapy, first-line regimens increasingly favor immunotherapy and targeted agents, with combination therapy strategies delivering synergistic tumor control. Second-line and later settings continue to benefit from alternate modality sequencing, where immunotherapy can succeed targeted treatments and vice versa. Biomarker-driven segmentation underscores this phenomenon: patients with ALK rearrangements or EGFR mutations are funneled to targeted inhibitors, whereas those exhibiting high PD-L1 expression are preferentially steered toward checkpoint inhibition. KRAS mutant subpopulations, once underserved, are now entering clinical evaluation for novel KRAS G12C inhibitors. Finally, distribution channel analysis highlights how hospital pharmacies remain the primary access point for intravenous therapies, while online and retail pharmacies are emerging as key players for oral targeted and adjuvant regimens, reflecting shifts toward decentralized care models.

Navigating Varied Regional Opportunities and Challenges

In the Americas, robust reimbursement frameworks and strong trial enrollment have solidified the United States as the epicenter of NSCLC therapeutic innovation. Canada and Latin American markets, while smaller, are witnessing gradual uptake of next-generation inhibitors as regulatory harmonization improves. Europe, the Middle East and Africa present a mosaic of market maturity: Western Europe leads adoption of immunotherapeutics and biomarker testing, while emerging markets in Eastern Europe and the Middle East face infrastructure and affordability constraints. Across Africa, access remains limited but pilot programs and philanthropic initiatives are laying the groundwork for future expansion.

Asia-Pacific exhibits a dynamic duality: Established markets like Japan and Australia rapidly integrate novel agents, supported by government-led precision medicine initiatives and local biomanufacturing. China’s expansive patient pool drives substantial investment in both homegrown biotech and international collaborations, accelerating approvals for domestic and imported therapies. Southeast Asian nations are scaling up their oncology ecosystems, yet challenges in diagnostic capacity and reimbursement continue to influence uptake. This regional tapestry underscores the necessity for tailored market entry strategies and collaborative stakeholder engagement across diverse healthcare environments.

Profiling Competitive Forces and Emerging Innovators

Leading pharmaceutical and biotechnology firms are jostling for position in the NSCLC arena through strategic alliances, targeted acquisitions and robust clinical pipelines. Established players hold ground through expanded label approvals for existing immunotherapies and targeted agents, leveraging real-world evidence to support line-of-therapy extensions and combination regimens. Simultaneously, emerging biotech companies are gaining momentum with novel modalities, such as antibody-drug conjugates and bispecific checkpoint inhibitors, that promise differentiated efficacy and safety profiles.

Collaborations between diagnostic developers and drug sponsors are intensifying as companion assays become prerequisites for precision prescribing. Contract research organizations and data analytics firms are also carving out niche roles by offering integrated trial management and predictive biomarker analytics. These competitive dynamics are further shaped by intellectual property landscapes, biosimilar entrants, and health technology assessment outcomes. Collectively, these forces are driving a fiercely innovative yet complex ecosystem in which agility and evidence-based differentiation are paramount.

Actionable Imperatives for Market Leadership

Leaders across the pharmaceutical, payer and provider spectrum must adopt a multipronged approach to capitalize on the evolving NSCLC market. First, integrating biomarker-driven patient selection into clinical decision support tools will optimize treatment outcomes and cost-effectiveness. Second, forging strategic partnerships with diagnostic and digital health companies can accelerate real-world evidence generation and enhance market access negotiations. Third, diversifying manufacturing and supply chain footprints will mitigate tariff-related risks and improve resilience. Fourth, proactively engaging with health technology assessment bodies and payers to demonstrate long-term value will secure favorable reimbursement pathways. Finally, investing in medical education and patient outreach programs will drive awareness of emerging therapies and encourage shared decision-making.

Transparent and Robust Methodological Framework

This analysis is grounded in a rigorous mixed-methods research approach, commencing with an exhaustive review of peer-reviewed literature, regulatory filings and clinical trial registries to capture the latest scientific developments. Quantitative intelligence was gathered through structured interviews with key opinion leaders in oncology, market access specialists and supply chain executives. These insights were triangulated with primary survey data from oncologists and hospital pharmacists across key global regions. Secondary data sources, including health economics databases and real-world evidence platforms, were leveraged to validate commercial trends. All findings were subjected to peer validation workshops and quality assurance protocols to ensure accuracy, neutrality and relevance.

Converging Trends Defining the Future of NSCLC Treatment

In conclusion, the NSCLC therapeutics landscape is at an inflection point characterized by converging scientific breakthroughs, policy shifts and competitive innovations. Immunotherapies have moved into earlier treatment settings, targeted inhibitors are continually refining efficacy against resistant mutations, and new modalities promise further incremental gains. Tariffs and supply chain adjustments underscore the importance of operational agility, while regional disparities highlight the need for tailored market strategies. As the field advances, stakeholders who align their research, development and commercialization efforts with patient-centric, evidence-based imperatives will emerge as the definitive leaders in this dynamic oncology domain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chemotherapy
    • Immunotherapy
      • CTLA-4 Inhibitors
        • Ipilimumab
      • PD-1 Inhibitors
        • Nivolumab
        • Pembrolizumab
      • PD-L1 Inhibitors
        • Atezolizumab
        • Avelumab
        • Durvalumab
    • Targeted Therapy
      • ALK Inhibitors
      • BRAF Inhibitors
      • EGFR Inhibitors
        • First Generation
        • Second Generation
        • Third Generation
      • ROS1 Inhibitors
  • Line Of Therapy
    • First Line
      • Chemotherapy
      • Combination Therapy
      • Immunotherapy
      • Targeted Therapy
    • Second Line
      • Chemotherapy
      • Combination Therapy
      • Immunotherapy
      • Targeted Therapy
    • Third Or Later
      • Chemotherapy
      • Combination Therapy
      • Immunotherapy
      • Targeted Therapy
  • Biomarker Expression
    • ALK Rearrangement
    • EGFR Mutant
    • High PD-L1 Expression
    • KRAS Mutant
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • BeiGene, Ltd.
  • Amgen Inc.
  • Regeneron Pharmaceuticals, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Non-small Cell Lung Cancer Therapeutics Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.3.1. CTLA-4 Inhibitors
8.3.1.1. Ipilimumab
8.3.2. PD-1 Inhibitors
8.3.2.1. Nivolumab
8.3.2.2. Pembrolizumab
8.3.3. PD-L1 Inhibitors
8.3.3.1. Atezolizumab
8.3.3.2. Avelumab
8.3.3.3. Durvalumab
8.4. Targeted Therapy
8.4.1. ALK Inhibitors
8.4.2. BRAF Inhibitors
8.4.3. EGFR Inhibitors
8.4.3.1. First Generation
8.4.3.2. Second Generation
8.4.3.3. Third Generation
8.4.4. ROS1 Inhibitors
9. Non-small Cell Lung Cancer Therapeutics Market, by Line of Therapy
9.1. Introduction
9.2. First Line
9.2.1. Chemotherapy
9.2.2. Combination Therapy
9.2.3. Immunotherapy
9.2.4. Targeted Therapy
9.3. Second Line
9.3.1. Chemotherapy
9.3.2. Combination Therapy
9.3.3. Immunotherapy
9.3.4. Targeted Therapy
9.4. Third Or Later
9.4.1. Chemotherapy
9.4.2. Combination Therapy
9.4.3. Immunotherapy
9.4.4. Targeted Therapy
10. Non-small Cell Lung Cancer Therapeutics Market, by Biomarker Expression
10.1. Introduction
10.2. ALK Rearrangement
10.3. EGFR Mutant
10.4. High PD-L1 Expression
10.5. KRAS Mutant
11. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Americas Non-small Cell Lung Cancer Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.3. Bristol-Myers Squibb Company
15.3.4. AstraZeneca PLC
15.3.5. Pfizer Inc.
15.3.6. Novartis AG
15.3.7. Takeda Pharmaceutical Company Limited
15.3.8. BeiGene, Ltd.
15.3.9. Amgen Inc.
15.3.10. Regeneron Pharmaceuticals, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 92. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 94. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 96. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 97. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 98. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 99. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 100. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 103. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 113. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 169. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 173. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 175. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 178. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 179. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 182. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 188. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 189. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 190. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 191. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 192. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 208. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 212. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 214. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 215. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 216. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 217. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 218. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 225. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 227. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 228. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 229. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 230. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 231. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 272. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 273. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 275. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. DENMARK NON-SMALL CELL LUNG CANCER THERAPEUTICS MA

Companies Mentioned

The companies profiled in this Non-small Cell Lung Cancer Therapeutics market report include:
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • BeiGene, Ltd.
  • Amgen Inc.
  • Regeneron Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 19.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 28.15 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Non Small Cell Lung Cancer Drug Market

The Non Small Cell Lung Cancer Drug market is a subset of the larger Lung Cancer Drug market. Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is typically treated with chemotherapy, radiation, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to healthy cells. The Non Small Cell Lung Cancer Drug market is highly competitive, with a number of companies offering various treatments. Companies such as AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer are some of the major players in the market. Other companies such as Amgen, Boehringer Ingelheim, and Novartis are also active in the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.